QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
Free Trial
NASDAQ:APTX

Aptinyx (APTX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free APTX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.09
▼
$0.10
50-Day Range
$0.06
▼
$0.10
52-Week Range
$0.01
▼
$0.72
Volume
231,100 shs
Average Volume
1.32 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisEarningsInsider TradesOwnershipSocial Media
APTX stock logo

About Aptinyx Stock (NASDAQ:APTX)

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

APTX Stock News Headlines

March 12, 2024 | benzinga.com
New Leaf Venture Management III, L.L.C.'s Net Worth
February 9, 2024 | benzinga.com
Patrick J Heron's Net Worth
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
January 13, 2024 | cnet.com
Best Noise-Canceling Headphones for 2024
December 17, 2023 | morningstar.com
Aptinyx Inc APTX
September 7, 2023 | morningstar.com
North American Morning Briefing: Concerns About -2-
March 30, 2023 | finance.yahoo.com
Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now
February 27, 2023 | finance.yahoo.com
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
January 31, 2023 | finance.yahoo.com
Aptinyx to Present at the SVB Securities Global Biopharma Conference
January 16, 2023 | ca.finance.yahoo.com
Aptinyx Inc. (APTX) Stock Historical Prices & Data - Yahoo Finance
January 5, 2023 | fool.com
Aptinyx (NASDAQ: APTX)
December 30, 2022 | insidermonkey.com
Aptinyx Inc. (NASDAQ:APTX) Q3 2022 Earnings Call Transcript
December 12, 2022 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Aptinyx (APTX)
November 8, 2022 | finance.yahoo.com
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
October 30, 2022 | fool.com
Aptinyx Inc. (NASDAQ: APTX)
October 18, 2022 | finance.yahoo.com
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 2, 2022 | reuters.com
APTX.OQ - Aptinyx Inc | Stock Price & Latest News | Reuters
September 24, 2022 | finance.yahoo.com
Aptinyx Inc. (APTX)
September 12, 2022 | nasdaq.com
Hopeful week for insiders who might be regretting buying US$567k of Aptinyx Inc. (NASDAQ:APTX) stock earlier this year - Nasdaq
August 26, 2022 | marketscreener.com
HC Wainwright Adjusts Price Target on Aptinyx to $1 From $2, Reiterates Buy Rating - Marketscreener.com
August 25, 2022 | businesswire.com
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies - Business Wire
August 25, 2022 | finance.yahoo.com
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
August 22, 2022 | finance.yahoo.com
Bullish Aptinyx Inc. (NASDAQ:APTX) investors are yet to receive a pay off on their US$567k bet
August 19, 2022 | nasdaq.com
Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates - Nasdaq
August 17, 2022 | morningstar.com
North American Morning Briefing: Investors Seek -2- - Morningstar
August 16, 2022 | markets.businessinsider.com
What 4 Analyst Ratings Have To Say About Aptinyx
See More Headlines
Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APTX
CUSIP
N/A
CIK
1674365
Web
www.aptinyx.com
Phone
(847) 871-0377
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$1 million
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.57 per share
Price / Book
0.17

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
1.27
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Craig R. Jalbert CIRA (Age 61)
    Principal Executive Officer, Fin. & Accounting Officer, President, Treasurer, Secretary and Director
  • Mr. Patrick Flavin
    Senior Manager of Corporate Development & Investor Relations
  • Ms. Molly Dir
    Vice President of Human Resources
  • Dr. Kathryn King Ph.D.
    Senior Vice President of Clinical & CMC Operations
  • Mr. Tim Noffke
    VP of Program Management & Chief of Staff
  • Dr. Harald Murck M.D.
    Ph.D., Vice President of Clinical & Medical Affairs

Key Competitors

View All Competitors

APTX Stock Analysis - Frequently Asked Questions

How were Aptinyx's earnings last quarter?

Aptinyx Inc. (NASDAQ:APTX) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). During the same period in the previous year, the firm earned ($0.24) earnings per share.

What other stocks do shareholders of Aptinyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Kadmon (KDMN), Matinas BioPharma (MTNB), Cidara Therapeutics (CDTX), ADMA Biologics (ADMA), DURECT (DRRX) and Catalyst Pharmaceuticals (CPRX).

When did Aptinyx IPO?

Aptinyx (APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

This page (NASDAQ:APTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The Next Nvidia?
InvestorPlace
How Biden has already won 2024
Porter & Company
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends